A global standard aimed beyond wealthy health systems
The World Health Organization issued its first guidelines on diagnosing and managing type 1 diabetes in adults on November 14. They are designed for ordinary clinics as well as low-resource, emergency and humanitarian settings. WHO estimates that about 9.5 million people lived with type 1 diabetes in 2025 and another 500,000 were diagnosed that year. Although associated with childhood, the condition also begins in adults and requires uninterrupted insulin for survival.[1][2]
Intensified treatment, with cost kept visible
WHO strongly recommends multiple daily insulin injections, with doses adjusted to blood-glucose readings. Both human insulin and analogues can be used, but the guidance prefers human insulin where cost is decisive because it is effective and generally cheaper. This is not a claim that every formulation is interchangeable for every patient. It is a procurement and clinical principle: scarce budgets should not prevent access to a workable basal and mealtime regimen.[1][2]
Monitoring recommendations scale with available resources
The guidance recommends regular clinical measurement of average glucose and self-monitoring at home. A finger-prick meter or continuous glucose monitor can be used; where blood testing is unavailable, urine glucose testing may be considered. That hierarchy recognises that the best technical option is not always obtainable in conflict zones or underfunded systems. It also makes monitoring equipment, test strips, refrigeration and trained staff part of the economic cost of insulin access rather than treating the vial alone as the entire service.[1][2]
Implementation is now the binding constraint
WHO’s 2030 targets call for universal access to affordable insulin and glucose self-monitoring for people with type 1 diabetes. Guidelines can standardise tenders, training and humanitarian kits, but they cannot by themselves fund supply chains or prevent stockouts. Countries will need to translate the recommendations into formularies, reimbursement and emergency continuity plans. The commercial consequence may be stronger emphasis on reliable, lower-cost human insulin alongside selective use of analogues and sensors where their additional benefit justifies the expense.[1][2]
Sources & evidence
- WHO issues first guidelines on type 1 diabetes for adults (opens in a new tab)World Health OrganizationSource language en
Current event, prevalence estimate, principal recommendations and 2030 access target.
Source note
Full public news release.
- Guidelines on insulin use for type 1 diabetes in adults, including in emergency and humanitarian settings (opens in a new tab)World Health OrganizationSource language en
Guideline scope, treatment strength, monitoring options and preference for lower-cost human insulin.
Source note
Overview and 125-page guideline publicly downloadable.